Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Earnings for Senseonics Holdings, Inc. (SENS)
Earnings in 2023 (TTM): $-60,392,000
According to Senseonics Holdings, Inc.'s latest financial reports the company's current earnings (TTM) are $-60,392,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Senseonics Holdings, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-60,392,000 | $-60,392,000 |
| 2022 | $142.12 M | $142.12 M |
| 2021 | $-302,475,000 | $-317,781,000 |
| 2020 | $-175,168,000 | $-191,024,000 |
| 2019 | $-115,549,000 | $-126,234,000 |
| 2018 | $-93,971,000 | $-93,971,000 |
| 2017 | $-59,101,000 | $-59,101,000 |
| 2016 | $-43,930,000 | $-43,930,000 |
| 2015 | $-29,877,000 | $-29,877,000 |
| 2014 | $-18,885,000 | $-18,885,000 |
| 2013 | $-18,779,000 | $-18,779,000 |